LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial.
Saved in:
| Title: | LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial. |
|---|---|
| Authors: | Dowlati A; Department of Medicine Division of Hematology and Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH, USA., Harvey RD; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA., Carvajal RD; Department of Medicine, Division of Hematology/Oncology, Columbia University, College of Physicians and Surgeons New York, New York, NY, USA., Hamid O; Department of Hematology/Oncology, The Angeles Clinic and Research Institute, Cedars-Sinai Affiliate, Los Angeles, CA, USA., Klempner SJ; Department of Medicine and Oncology, Massachusetts General Hospital, Boston, MA, USA., Kauh JSW; Medical Oncology, Hutchison MediPharma Inc., Florham Park, NJ, USA., Peterson DA; Eli Lilly and Company, Indianapolis, IN, USA., Yu D; Eli Lilly and Company, Indianapolis, IN, USA., Chapman SC; Eli Lilly and Company, Windlesham, Surrey, UK., Szpurka AM; Eli Lilly and Company, Indianapolis, IN, USA., Carlsen M; Eli Lilly and Company, Indianapolis, IN, USA., Quinlan T; Eli Lilly and Company, Indianapolis, IN, USA., Wesolowski R; Internal Medicine, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, 1310D Lincoln Tower, 1800 Cannon Drive, Columbus, OH, 43210, USA. Robert.Wesolowski@osumc.edu. |
| Source: | Investigational new drugs [Invest New Drugs] 2021 Aug; Vol. 39 (4), pp. 1057-1071. Date of Electronic Publication: 2021 Feb 23. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 33624233 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Dowlati+A%22">Dowlati A</searchLink>; Department of Medicine Division of Hematology and Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH, USA.<br /><searchLink fieldCode="AU" term="%22Harvey+RD%22">Harvey RD</searchLink>; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.<br /><searchLink fieldCode="AU" term="%22Carvajal+RD%22">Carvajal RD</searchLink>; Department of Medicine, Division of Hematology/Oncology, Columbia University, College of Physicians and Surgeons New York, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Hamid+O%22">Hamid O</searchLink>; Department of Hematology/Oncology, The Angeles Clinic and Research Institute, Cedars-Sinai Affiliate, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Klempner+SJ%22">Klempner SJ</searchLink>; Department of Medicine and Oncology, Massachusetts General Hospital, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Kauh+JSW%22">Kauh JSW</searchLink>; Medical Oncology, Hutchison MediPharma Inc., Florham Park, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Peterson+DA%22">Peterson DA</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Yu+D%22">Yu D</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Chapman+SC%22">Chapman SC</searchLink>; Eli Lilly and Company, Windlesham, Surrey, UK.<br /><searchLink fieldCode="AU" term="%22Szpurka+AM%22">Szpurka AM</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Carlsen+M%22">Carlsen M</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Quinlan+T%22">Quinlan T</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Wesolowski+R%22">Wesolowski R</searchLink>; Internal Medicine, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, 1310D Lincoln Tower, 1800 Cannon Drive, Columbus, OH, 43210, USA. Robert.Wesolowski@osumc.edu. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228309330%22">Investigational new drugs</searchLink> [Invest New Drugs] 2021 Aug; Vol. 39 (4), pp. 1057-1071. <i>Date of Electronic Publication: </i>2021 Feb 23. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer%22">Springer </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309330 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1573-0646 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201676997%22">01676997 </searchLink><i>NLM ISO Abbreviation: </i>Invest New Drugs <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=33624233 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s10637-021-01084-8 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1057 Titles: – TitleFull: LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Dowlati A – PersonEntity: Name: NameFull: Harvey RD – PersonEntity: Name: NameFull: Carvajal RD – PersonEntity: Name: NameFull: Hamid O – PersonEntity: Name: NameFull: Klempner SJ – PersonEntity: Name: NameFull: Kauh JSW – PersonEntity: Name: NameFull: Peterson DA – PersonEntity: Name: NameFull: Yu D – PersonEntity: Name: NameFull: Chapman SC – PersonEntity: Name: NameFull: Szpurka AM – PersonEntity: Name: NameFull: Carlsen M – PersonEntity: Name: NameFull: Quinlan T – PersonEntity: Name: NameFull: Wesolowski R IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 08 Text: 2021 Aug Type: published Y: 2021 Identifiers: – Type: issn-electronic Value: 1573-0646 Numbering: – Type: volume Value: 39 – Type: issue Value: 4 Titles: – TitleFull: Investigational new drugs Type: main |
| ResultId | 1 |
